akn-028
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01573247)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
FLT3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1- Mol. weight
- 302.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4790100 ↗
- ChEMBLCHEMBL3545281 ↗
Also known as
- akn-028
- akn-028
- akn-028
- akn-028
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01573247 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2011 | Akinion Pharmaceuticals AB, Uppsala University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akinion Pharmaceuticals AB | For profit | 1 | 1 | 1 | 2011 |
| Uppsala University | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1